These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8684513)

  • 21. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin.
    Cosi V; Lombardi M; Piccolo G; Erbetta A
    Acta Neurol Scand; 1991 Aug; 84(2):81-4. PubMed ID: 1950455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child.
    Saulat B; Maertens P; Hamilton WJ; Bassam BA
    Neurology; 2007 Aug; 69(8):803-4. PubMed ID: 17709714
    [No Abstract]   [Full Text] [Related]  

  • 23. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of myasthenia gravis with anti-MuSK antibodies showing a dramatic improvement with plasma exchange].
    Suzuki H; Motomura M; Yoshimura T; Shiraishi H; Mitsui Y; Hasegawa T; Atsumi M; Kitaguchi M; Kusunoki S
    Rinsho Shinkeigaku; 2005 Jul; 45(7):510-3. PubMed ID: 16119834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmapheresis in the treatment of myasthenia gravis.
    Lenzhofer R; Graninger W; Dittrich C; Mamoli B; Zeitlhofer J; Pateisky K
    Wien Klin Wochenschr; 1983 Apr; 95(8):266-71. PubMed ID: 6603717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.
    Strober J; Cowan MJ; Horn BN
    Arch Neurol; 2009 May; 66(5):659-61. PubMed ID: 19433668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D-Penicillamine-associated myasthenia gravis: immunological and electrophysiological studies.
    Fawcett PR; McLachlan SM; Nicholson LV; Argov Z; Mastaglia FL
    Muscle Nerve; 1982 Apr; 5(4):328-34. PubMed ID: 7099199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis].
    Tatay J; Díez-Tejedor E; Frank A; Tejada J; Marrero C; Barreiro P
    Rev Neurol; 1997 Sep; 25(145):1402-6. PubMed ID: 9377299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
    Ferrero B; Durelli L
    Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Seronegative myasthenia gravis].
    Bilińska M
    Pol Merkur Lekarski; 2002 Jan; 12(67):49-53. PubMed ID: 11957803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of therapeutic plasmapheresis in patients with generalized myasthenia during exacerbations in the late period following thymectomy].
    Marchuk AI; Golovteev VV; Sapin SM; Shagal DI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(3):330-3. PubMed ID: 3705836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Myasthenia gravis with electrophysiological features of Lambert-Eaton myasthenic syndrome: usefulness of serum autoantibodies assay and neuromuscular junction biopsy].
    Matsumoto R; Motomura M; Yoshimura T; Kohara N; Kato T
    Rinsho Shinkeigaku; 1999 May; 39(5):531-7. PubMed ID: 10424144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
    Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
    J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical study of double filtration plasmapheresis for treatment of refractory myasthenia gravis].
    Huo JT; Long HL; Luo X; Xu JZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):355-7. PubMed ID: 17425991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment of severe forms of myasthenia gravis.
    Iani C; Caramia M; Morosetti M; Loberti M; Palmieri MG; Meloni C; Gallucci MT; Casciani CU; Bernardi G
    Funct Neurol; 1998; 13(3):231-7. PubMed ID: 9800150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ocular myasthenia: a diagnostic and management challenge--a review].
    Langmann A; Lindner S; Koch M; Diez J
    Klin Monbl Augenheilkd; 2004 Feb; 221(2):77-86. PubMed ID: 14986204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myasthenia gravis.
    Khadilkar SV; Sahni AO; Patil SG
    J Assoc Physicians India; 2004 Nov; 52():897-904. PubMed ID: 15906843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
    Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
    Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
    Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
    J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.